Study: Combo therapy cuts death risk from cryptococcal meningitis

04/4/2013 | HealthDay News

A treatment regimen that combines the antifungal drugs amphotericin B and flucytosine can lower cryptococcal meningitis patients' risk of death by 40% compared to amphotericin B alone, a study in the New England Journal of Medicine showed. Survivors also had lower odds of disability if they were treated with flucytosine, the researchers found.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA